Takeji NISHIKAWA, M. D.*, Takashi HARADA, M. D.** and Tatsuya IZUML M. D. Toshiyuki SUGI, M. D. Hiroshi HANYAKU, M. D. Shun-ichi MIYAKAWA, M. D. and Masaru TANAKA, M. D. Nobuko INAMOTO, M. D. and Hironori NIIZEKI, M. D. Makoto SUGAWARA, M. D. and Hirokuni TERAMOTO, M. D. Yuichiro YAMASAKI, M. D. and Takashi KOBAYASHI, M. D. Koichi SAKURAOKA, M. D. and Yoshie KAWAHARA, M. D. Makoto SUGIURA, M. D. and Yuko SASAKI, M. D. Reiko HARADA, M. D. Hideo NAKAYAMA, M. D. and Misa SAKURAI, M. D. Izumi KONOHANA, M. D.

Clinical Study of "Eclar(R) Ointment" (Deprodone Propionate) on Eczema and Dermatitis in Childhood Takeji Nishikawa, Takashi Harada and Tatsuya Izumi Department of Dermatology, Keio University Hospital 35, Shinanomachi, Shinjuku-ku, Tokyo 160, Japan Toshiyuki Sugi Division of Dermatology, Urawa Hospital Hiroshi Hanyaku Division of Dermatology, Ogikubo Hospital Shun-ichi Miyakawa and Masaru Tanaka Division of Dermatology, Kawasaki Municipal Hospital Nobuko Inamoto and Hironori Niizeki Division of Dermatology, Kitasato Institute Hospital Makoto Sugawara and Hirokuni Teramoto Division of Dermatology, Keiyu General Hospital Yuichiro Yamasaki and Takashi Kobayashi Division of Dermatology, The Second Tokyo National Hospital Koichi Sakuraoka and Yoshie Kawahara Division of Dermatology, Saiseikai Yokohama Hospital for Southern Disprict Makoto Sugiura and Yuko Sasaki Division of Dermatology, Shimizu City Hospital Reiko Harada Division of Dermatology, Tokyo Electric Power Hospital Hideo Nakayama and Misa Sakurai Division of Dermatology, Saiseikai Central Hospital Izumi Konohana Division of Dermatology, Hiratsuka City Hospital Key words: deprodone propionate-topical steroid-eczema and dermatitis in childhood To confirm the efficacy, safety and usefulness of Eclar(R) ointment and cream in childhood, a post-marketing clinical study was investigated. Eclar(R) ointment and cream contain 0.3% deprodone propionate as synthesized adrenal corticoid hormone. Eclar(R) ointment and cream were topically applied to the following 56 patients of children 40 exudative dermatitis (36 patients on ointment and 4 patients on cream) and 16 lichenified dermatitis (13 patients on ointment and 3 patients on cream). The rate of efficacy on 49 cases treated with ointment was 87.8% as overall evaluated "improved", and 100.0% as overall evaluated "slightly improved". The number of cases treated with cream were too few (7 cases) to be evaluated for analysis of efficacy. From these results, it is estimated that Eclar(R) ointment is effective, safe and useful as topical treatment on eczema and dermatitis in childhood.